Driving Progress in Preclinical Dravet Syndrome Research

PsychoGenics is highly experienced in preclinical studies of Dravet syndrome, a rare and debilitating genetic disorder characterized by severe and prolonged seizures, typically beginning in infancy. 

Dravet syndrome is caused by a mutation in the SCN1A gene, which disrupts the normal functioning of sodium channels in the brain. Individuals affected by Dravet syndrome often experience various types of seizures, developmental delays, cognitive impairments, and other neurological challenges.

PsychoGenics’ Dravet Syndrome Models and Capabilities

At PsychoGenics, we are committed to advancing the understanding and treatment of this disease through the utilization of rodent models designed specifically for Dravet syndrome.

Our Rodent Models of Dravet Syndrome

In our preclinical Dravet syndrome studies, PsychoGenics utilizes heterozygous conditional knock-in mice (B6(Cg)-Scn1a^tm1.1Dsf/J) with the A1783V missense mutation in the SCN1A gene. When exposed to Cre recombinase, these mice exhibit Dravet-like phenotypes, including spontaneous seizures. 

By leveraging our expertise in preclinical disease models, we aim to identify underlying mechanisms and advance the development of your novel therapy. 

Leading the Way in Dravet Syndrome Research: Fostering Your Breakthrough 

At PsychoGenics, collaboration is instrumental in driving progress in preclinical Dravet syndrome research. Through robust partnerships, we strive to enhance our understanding of this disorder and develop effective strategies to support your research. Engage with us to accelerate your next breakthrough.